Trials / Completed
CompletedNCT06072235
Facemasks and Chronic Pain Patients With Hearing Loss
Facemasks and COVID-19 Pandemic in Chronic Pain Patients With Hearing Impairment
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (actual)
- Sponsor
- Salem Anaesthesia Pain Clinic · Academic / Other
- Sex
- All
- Age
- 20 Years – 99 Years
- Healthy volunteers
- Accepted
Summary
Facemasks may impede communication. Impaired communication may worsen healthcare outcomes. This study explores the problem of hearing impairment in chronic pain patients, and the impact of facemasks on healthcare outcomes in chronic pain patients. Data collection includes patient's age, anxiety score, depression score, numeric pain score, and effects of facemasks on treatment outcomes. Pain is measured using numeric pain rating scale. Depression is measured using the Patient Health Questionnaire (PHQ-9) scale. Anxiety is measured using the General Anxiety Disorder (GAD-7) scale.
Detailed description
Facemasks may impede communication. Impaired communication may worsen healthcare outcomes. There is inadequate data on the prevalence of hearing impairment in chronic pain patients. There is inadequate information about the impact of facemasks on treatment outcomes in chronic pain patients with hearing impairment. This prospective study explores the problem of hearing impairment in chronic pain patients, and the impact of facemasks on healthcare outcomes in chronic pain patients. This is a prospective cohort study of adult patients undergoing pain treatment at an interventional pain clinic in Canada. Data collection includes patient's age, anxiety score, depression score, analgesic usage, numeric pain score, and effects of facemasks on pain management outcomes. Pain is measured using numeric pain rating scale of 0-10, with change of 2-points being considered significant. Depression is measured using the Patient Health Questionnaire (PHQ-9) scale of 0-27, with change of 3-points being considered significant. Anxiety is measured using the General Anxiety Disorder (GAD-7) scale of 0-21, with change of 3-points being considered significant. Data are analyzed with IBM® SPSS® Statistics 25; using Student's t-test, ANOVA, Pearson Chi-square test, and regression analysis. P-value \<0.05 is considered significant.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BEHAVIORAL | Verbal communication | Verbal communication; by talking and listening |
Timeline
- Start date
- 2018-01-08
- Primary completion
- 2024-12-11
- Completion
- 2024-12-11
- First posted
- 2023-10-10
- Last updated
- 2025-01-27
Locations
1 site across 1 country: Canada
Source: ClinicalTrials.gov record NCT06072235. Inclusion in this directory is not an endorsement.